April 30th 2025
The company’s intent is to establish Merck Wilmington Biotech as the future United States home for producing Keytruda for US patients.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Targeted Delivery of Gene and Cell Therapies
August 1st 2015Gene and cell therapies represent the next-generation treatments for a wide range of diseases, but one challenge in the development of these therapeutics is the controlled delivery to the targeted site to maximize expression or engraftment while limiting systemic exposure.
EMA Releases Positive Opinion for GSK’s Malaria Vaccine
July 24th 2015The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive scientific opinion for GlaxoSmithKline’s (GSK’s) malaria candidate vaccine Mosquirix (RTS,S) for use outside of the European Union (EU) in children aged 6 weeks to 17 months.